Millennium, Seattle Gen (SGEN) to Present Brentuximab Vedotin Data

Millennium: The Takeda Oncology Company and Seattle Genetics, Inc. (Nasdaq: SGEN) reports that an oral presentation and a poster presentation featuring brentuximab vedotin (SGN-35) will be presented at the 16th Congress of the European Hematology Association (EHA) being held from June 9-12, 2011, in London.

Information about the presentations:

Hodgkin Lymphoma

• Objective responses with brentuximab vedotin (SGN-35) in patients with relapsed or refractory Hodgkin lymphoma (HL) who refused or were ineligible for autologous stem cell transplantation (ASCT)
  
  
• Presenter: Ranjana Advani, M.D., Stanford Advanced Medicine Cancer Center, Stanford University, Stanford, California
  
  
• Data from patients with relapsed or refractory HL who refused or were ineligible for ASCT in Phase I trials of brentuximab vedotin
  
  
• Abstract #938: Oral presentation session: Saturday, June 11, 2011; 4:45 P.M. GMT

Systemic ALCL

• Resolution of malignant cutaneous lesions with brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large cell lymphoma (ALCL)
  
  
• Presenter: Ranjana Advani, M.D., Stanford Advanced Medicine Cancer Center, Stanford University, Stanford, California
  
  
• Data on patients with relapsed or refractory systemic ALCL who had malignant cutaneous lesions treated on a Phase II, single-arm, multicenter study
  
  
• Abstract #1042: Poster presentation session: Friday, June 10, 2011; 5:45 P.M. GMT

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Alphabet (GOOGL) soars 16% on Q1 results beat, first-ever dividend
• Roper's (ROP) iPipeline Appoints Adam Boone as CFO
• Central Securities (CET) Releases Report to Stockholders